Human Genetics Market By Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others) , By Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment) : Global Opportunity Analysis and Industry Forecast, 2024-2033

September 2024 | 320 pages | ID: H774A94E4732EN
Allied Market Research

Abstracts

Human Genetics Market Expected to Garner $71.1 Billion by 2033, Growing at a CAGR of 10.8%

Abstract: The global human genetics market is expected to grow primarily due to the growing prevalence of genetic disorders and rising application of genetics in oncology, rare diseases, & infectious diseases. The North America region is predicted to witness profitable growth by 2033.

As per the report published by Research Dive, the global human genetics market was valued at $27.0 billion in 2023 and is expected to register a revenue of $71.1 billion by 2033 at a CAGR of 10.8% during the forecast period 2024-2033.

Dynamics of the Market

The rising prevalence of genetic disorders in newborns, growth in direct-to-consumer genetic testing and personalized genomics, and increasing application of genetics in oncology, rare diseases, & infectious diseases are expected to make the human genetics market a highly profitable one during the forecast period.

However, according to market analysts, concerns about genetic data privacy and potential misuse of genetic information might restrain the growth of the market.

Advances in patterned flow cell technology and expansion of biotechnology & pharmaceutical collaborations in genetic research present significant opportunities for human genetics market growth. Moreover, the development and application of cutting-edge technologies, such as patterned flow cell technology, offer opportunities for more efficient and accurate genetic analysis.

Key Players of the Market

The major players of the human genetics market include Myriad Genetics, Eurofins Megalab S.A, Synlab Group, Biomarker Technology, Elabscience Biotechnology Inc, Echevarne Laboratory, NIMGenetics, FullGenomics, Sistemas Genуmicos, Atrys Health, and GENinCode.

What the Report Covers

In addition to the details highlighted in this description, the comprehensive final report delves into essential market aspects. These encompass a market overview, SWOT analysis, market dynamics, Porter’s five forces analysis, segmentation (key trends, regional analysis, and forecast analysis), and company profiles (including company overview, product portfolio, operating segments, strategic initiatives, and financial performance).

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Product Life Cycles
• Technology Trend Analysis
• Market share analysis of players by products/segments
• New Product Development/ Product Matrix of Key Players
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• Market share analysis of players at global/region/country level
• SWOT Analysis

Key Market Segments

By Test

• NIPT
• Carrier Testing
• Pharmacogenomic Testing
• Karyotype Testing
• Thrombophilia Testing
• Septin 9 Biomarker Testing
• NGS
• Others

By Application

• Wellness E-Commerce
• Preventive Medicine
• Diagnostic Treatment

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• France
• Germany
• Italy
• Spain
• UK
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia-Pacific
• LAMEA
• Brazil
• South Africa
• Saudi Arabia
• UAE
• Rest of LAMEA
• Key Market Players
• Myriad Genetics
• Synlab Group
• Eurofins Megalab S.A.
• Biomarker Technologies
• Echevarne Laboratory
• Elabscience Biotechnology Inc
• nimgenetics
• Sistemas Genуmicos
• FullGenomics
• GENinCode
• atrys health

Contents

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
  1.4.1. Primary Research
  1.4.2. Secondary Research
  1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
  3.2.1. Top Investment Pockets
  3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
  3.3.1. Bargaining Power of Suppliers
  3.3.2. Threat of New Entrants
  3.3.3. Threat of Substitutes
  3.3.4. Competitive Rivalry
  3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
  3.4.1. Drivers
  3.4.2. Restraints
  3.4.3. Opportunities

CHAPTER 4: HUMAN GENETICS MARKET, BY TEST

4.1. Market Overview
  4.1.1 Market Size and Forecast, By Test
4.2. NIPT
  4.2.1. Key Market Trends, Growth Factors and Opportunities
  4.2.2. Market Size and Forecast, By Region
  4.2.3. Market Share Analysis, By Country
4.3. Carrier Testing
  4.3.1. Key Market Trends, Growth Factors and Opportunities
  4.3.2. Market Size and Forecast, By Region
  4.3.3. Market Share Analysis, By Country
4.4. Pharmacogenomic Testing
  4.4.1. Key Market Trends, Growth Factors and Opportunities
  4.4.2. Market Size and Forecast, By Region
  4.4.3. Market Share Analysis, By Country
4.5. Karyotype Testing
  4.5.1. Key Market Trends, Growth Factors and Opportunities
  4.5.2. Market Size and Forecast, By Region
  4.5.3. Market Share Analysis, By Country
4.6. Thrombophilia Testing
  4.6.1. Key Market Trends, Growth Factors and Opportunities
  4.6.2. Market Size and Forecast, By Region
  4.6.3. Market Share Analysis, By Country
4.7. Septin 9 Biomarker Testing
  4.7.1. Key Market Trends, Growth Factors and Opportunities
  4.7.2. Market Size and Forecast, By Region
  4.7.3. Market Share Analysis, By Country
4.8. NGS
  4.8.1. Key Market Trends, Growth Factors and Opportunities
  4.8.2. Market Size and Forecast, By Region
  4.8.3. Market Share Analysis, By Country
4.9. Others
  4.9.1. Key Market Trends, Growth Factors and Opportunities
  4.9.2. Market Size and Forecast, By Region
  4.9.3. Market Share Analysis, By Country

CHAPTER 5: HUMAN GENETICS MARKET, BY APPLICATION

5.1. Market Overview
  5.1.1 Market Size and Forecast, By Application
5.2. Wellness E-Commerce
  5.2.1. Key Market Trends, Growth Factors and Opportunities
  5.2.2. Market Size and Forecast, By Region
  5.2.3. Market Share Analysis, By Country
5.3. Preventive Medicine
  5.3.1. Key Market Trends, Growth Factors and Opportunities
  5.3.2. Market Size and Forecast, By Region
  5.3.3. Market Share Analysis, By Country
5.4. Diagnostic Treatment
  5.4.1. Key Market Trends, Growth Factors and Opportunities
  5.4.2. Market Size and Forecast, By Region
  5.4.3. Market Share Analysis, By Country

CHAPTER 6: HUMAN GENETICS MARKET, BY REGION

6.1. Market Overview
  6.1.1 Market Size and Forecast, By Region
6.2. North America
  6.2.1. Key Market Trends and Opportunities
  6.2.2. Market Size and Forecast, By Test
  6.2.3. Market Size and Forecast, By Application
  6.2.4. Market Size and Forecast, By Country
  6.2.5. U.S. Human Genetics Market
    6.2.5.1. Market Size and Forecast, By Test
    6.2.5.2. Market Size and Forecast, By Application
  6.2.6. Canada Human Genetics Market
    6.2.6.1. Market Size and Forecast, By Test
    6.2.6.2. Market Size and Forecast, By Application
  6.2.7. Mexico Human Genetics Market
    6.2.7.1. Market Size and Forecast, By Test
    6.2.7.2. Market Size and Forecast, By Application
6.3. Europe
  6.3.1. Key Market Trends and Opportunities
  6.3.2. Market Size and Forecast, By Test
  6.3.3. Market Size and Forecast, By Application
  6.3.4. Market Size and Forecast, By Country
  6.3.5. France Human Genetics Market
    6.3.5.1. Market Size and Forecast, By Test
    6.3.5.2. Market Size and Forecast, By Application
  6.3.6. Germany Human Genetics Market
    6.3.6.1. Market Size and Forecast, By Test
    6.3.6.2. Market Size and Forecast, By Application
  6.3.7. Italy Human Genetics Market
    6.3.7.1. Market Size and Forecast, By Test
    6.3.7.2. Market Size and Forecast, By Application
  6.3.8. Spain Human Genetics Market
    6.3.8.1. Market Size and Forecast, By Test
    6.3.8.2. Market Size and Forecast, By Application
  6.3.9. UK Human Genetics Market
    6.3.9.1. Market Size and Forecast, By Test
    6.3.9.2. Market Size and Forecast, By Application
  6.3.10. Rest Of Europe Human Genetics Market
    6.3.10.1. Market Size and Forecast, By Test
    6.3.10.2. Market Size and Forecast, By Application
6.4. Asia-Pacific
  6.4.1. Key Market Trends and Opportunities
  6.4.2. Market Size and Forecast, By Test
  6.4.3. Market Size and Forecast, By Application
  6.4.4. Market Size and Forecast, By Country
  6.4.5. China Human Genetics Market
    6.4.5.1. Market Size and Forecast, By Test
    6.4.5.2. Market Size and Forecast, By Application
  6.4.6. Japan Human Genetics Market
    6.4.6.1. Market Size and Forecast, By Test
    6.4.6.2. Market Size and Forecast, By Application
  6.4.7. India Human Genetics Market
    6.4.7.1. Market Size and Forecast, By Test
    6.4.7.2. Market Size and Forecast, By Application
  6.4.8. South Korea Human Genetics Market
    6.4.8.1. Market Size and Forecast, By Test
    6.4.8.2. Market Size and Forecast, By Application
  6.4.9. Australia Human Genetics Market
    6.4.9.1. Market Size and Forecast, By Test
    6.4.9.2. Market Size and Forecast, By Application
  6.4.10. Rest of Asia-Pacific Human Genetics Market
    6.4.10.1. Market Size and Forecast, By Test
    6.4.10.2. Market Size and Forecast, By Application
6.5. LAMEA
  6.5.1. Key Market Trends and Opportunities
  6.5.2. Market Size and Forecast, By Test
  6.5.3. Market Size and Forecast, By Application
  6.5.4. Market Size and Forecast, By Country
  6.5.5. Brazil Human Genetics Market
    6.5.5.1. Market Size and Forecast, By Test
    6.5.5.2. Market Size and Forecast, By Application
  6.5.6. South Africa Human Genetics Market
    6.5.6.1. Market Size and Forecast, By Test
    6.5.6.2. Market Size and Forecast, By Application
  6.5.7. Saudi Arabia Human Genetics Market
    6.5.7.1. Market Size and Forecast, By Test
    6.5.7.2. Market Size and Forecast, By Application
  6.5.8. UAE Human Genetics Market
    6.5.8.1. Market Size and Forecast, By Test
    6.5.8.2. Market Size and Forecast, By Application
  6.5.9. Rest of LAMEA Human Genetics Market
    6.5.9.1. Market Size and Forecast, By Test
    6.5.9.2. Market Size and Forecast, By Application

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

8.1. Myriad Genetics
  8.1.1. Company Overview
  8.1.2. Key Executives
  8.1.3. Company Snapshot
  8.1.4. Operating Business Segments
  8.1.5. Product Portfolio
  8.1.6. Business Performance
  8.1.7. Key Strategic Moves and Developments
8.2. Synlab Group
  8.2.1. Company Overview
  8.2.2. Key Executives
  8.2.3. Company Snapshot
  8.2.4. Operating Business Segments
  8.2.5. Product Portfolio
  8.2.6. Business Performance
  8.2.7. Key Strategic Moves and Developments
8.3. Eurofins Megalab S.A.
  8.3.1. Company Overview
  8.3.2. Key Executives
  8.3.3. Company Snapshot
  8.3.4. Operating Business Segments
  8.3.5. Product Portfolio
  8.3.6. Business Performance
  8.3.7. Key Strategic Moves and Developments
8.4. Biomarker Technologies
  8.4.1. Company Overview
  8.4.2. Key Executives
  8.4.3. Company Snapshot
  8.4.4. Operating Business Segments
  8.4.5. Product Portfolio
  8.4.6. Business Performance
  8.4.7. Key Strategic Moves and Developments
8.5. Echevarne Laboratory
  8.5.1. Company Overview
  8.5.2. Key Executives
  8.5.3. Company Snapshot
  8.5.4. Operating Business Segments
  8.5.5. Product Portfolio
  8.5.6. Business Performance
  8.5.7. Key Strategic Moves and Developments
8.6. Elabscience Biotechnology Inc
  8.6.1. Company Overview
  8.6.2. Key Executives
  8.6.3. Company Snapshot
  8.6.4. Operating Business Segments
  8.6.5. Product Portfolio
  8.6.6. Business Performance
  8.6.7. Key Strategic Moves and Developments
8.7. Nimgenetics
  8.7.1. Company Overview
  8.7.2. Key Executives
  8.7.3. Company Snapshot
  8.7.4. Operating Business Segments
  8.7.5. Product Portfolio
  8.7.6. Business Performance
  8.7.7. Key Strategic Moves and Developments
8.8. Sistemas Genуmicos
  8.8.1. Company Overview
  8.8.2. Key Executives
  8.8.3. Company Snapshot
  8.8.4. Operating Business Segments
  8.8.5. Product Portfolio
  8.8.6. Business Performance
  8.8.7. Key Strategic Moves and Developments
8.9. FullGenomics
  8.9.1. Company Overview
  8.9.2. Key Executives
  8.9.3. Company Snapshot
  8.9.4. Operating Business Segments
  8.9.5. Product Portfolio
  8.9.6. Business Performance
  8.9.7. Key Strategic Moves and Developments
8.10. GENinCode
  8.10.1. Company Overview
  8.10.2. Key Executives
  8.10.3. Company Snapshot
  8.10.4. Operating Business Segments
  8.10.5. Product Portfolio
  8.10.6. Business Performance
  8.10.7. Key Strategic Moves and Developments
8.11. Atrys Health
  8.11.1. Company Overview
  8.11.2. Key Executives
  8.11.3. Company Snapshot
  8.11.4. Operating Business Segments
  8.11.5. Product Portfolio
  8.11.6. Business Performance
  8.11.7. Key Strategic Moves and Developments